Antibody Drug Conjugate and Big Pharmaceutical Companies Boom
Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success, more companies are looking to produce these drugs. Although antibody-drug conjugates show promise in the development of effective cancer therapies, there are still a variety of challenges involved in enabling the safe manufacture of these hazardous drugs. ADC’s continues to gain popularity but the market is in infant stage with only 3 drugs approved by U.S. FDA.
- Mylotarg from Wyeth (now Pfizer) was the 1st drug approved for the treatment of acute myeloid leukaemia back in 2000 but was withdrawn a decade later.
- Adcetris (brentuximab vedotin) from Seattle Genetics was approved by the FDA in 2011 for the treatment of Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma.
- Genentech’s Kadcyla (ado-trastuzumab emtansine) was given FDA approval in early 2013. ImmunoGen holds patents on Kadcyla and how it is manufactured, and receive royalties from Roche on its sales.
More than 264 Antibody-drug conjugates are under pipeline and as the large numbers of pharmaceutical companies are involved in antibody-drug conjugates market, therefore it is expected that this market will grow rapidly.
Although the market now has presence of many large pharmaceutical companies, but the technology lies with only few. Seattle Genetics and ImmunoGen are the pioneers in technology licensing, with most drugs using their technology.
The future of ADCs in the biopharmaceutical market will ultimately depend on their clinical success. Companies and researchers are seeking to meet that challenge by optimizing the selection of all the components in the ADC—the antibody, linker, and cytotoxin—and successfully combining manufacturing techniques for both high- potency APIs and biologics. Earlier unsuccessful attempts to generate ADCs with therapeutic value have emphasized the important role each component plays in determining the efficacy and safety of the final ADC.
Since ADC’s are highly complex to manufacture, it provides unique opportunities and challenges to Contract Manufacturers Organizations (CMOs) and biopharmaceutical companies seeking CMP partners for their ADC candidates.
In some cases, three separate CMOs are utilized- one for the chemical linker, one for the antibody and one for the highly potent drug. Then, everything is shipped to someone else for conjugation.
Some CMO’s which offer ADC Conjugation services include: Lonza, Laureate Biopharma, Piramal Healthcare Pharma Solutions, Abbott contracts manufacturing, Aquitaine Pharm International, etc.
ADCs are sometimes described as armed antibodies, and their cytotoxic components as warheads. Whether ADCs will prove to be an effective weapon against cancer or other diseases has yet to be seen as more are tested in the clinic.
By Shriya Sahni, Associate Analyst, DelveInsight
For more information on this Report, please mail at info@delveInsight.com
DelveInsight’s Mechanism of Action Reports has become the Success Reason for the Leading Pharma Companies
In this competitive world, everybody wants to get aware of what others are doing in their sectors and what strategic drivers are followed by the others for the successful future milestones. But the drug future is only dependent on one thing and that is how much efficacy it is showing through its mechanism of action to improve the medical condition. So utilizing the most effective targets and technology, the drug can do million dollar business.
DelveInsight released Mechanism of Action reports provides the targets-mode of action based information-across all the therapy under research work, pipeline products across all the companies, current technology, molecule type, stage, company finances, comparative analysis and therapeutic assessment at every step. These Reports propose specific strategies that could have the most substantial impact in improving R&D productivity.
“We are really happy that our reports are showing potential in the market. We have become a strategic partner for the Pharma Companies worldwide” said Dr. B.K. Agrawal, Managing Partner at DelveInsight Business Research.
These Reports highlights therapeutic targets and their mode of action; for instance Inflammatory targets: Reversible Anticholinesterases, Sphingosine 1-Phosphate (S1P) Inhibitors, c-jun-N-Terminal Kinase (JNK) inhibitors, Cancer Targets: Gamma Secretase inhibitors, IL-13 Receptor Antagonists and many more…..
DelveInsight’s Mechanism of Action reports is not only gaining importance but also has become the most known among the clients.
These reports are available with many resellers like Report Linkers, Report Buyers, Research moz, ASD Reports, Report Stack, Bharat Book Bureau and Market Reports.
Ask for sample reports now!
For more information please contact firstname.lastname@example.org
DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports.
Infectious Diseases and Vaccines
The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a first vaccine, and even routine vaccinations, such as those for influenza can be improved in terms of safety and efficacy. Such unmet needs are driving the continued development of ID vaccines.
Get Notified About Whats in Others Pipeline
The research work for curing Infectious disease has rapidly assumed a prioritized role within the overall scientific portfolio. The number of vaccines development underway has increased substantially for the HCV, HIV, Tuberculosis and Influenza infections.
Get notified about all the under development vaccines worldwide and the technology they are using, stage of development, their targets, mechanism of action with our Pipeline reports. The best strategic report that will not even give you the overall developing drug profiles but also therapeutic assessment and comparative analysis at every step such as monotherapy, combination, route of administration.
Pipeline Insights Reports
HCV Vaccine-Pipeline Insights, 2014
HIV Vaccine-Pipeline Insights, 2014
Influenza Vaccine-Pipeline Insights, 2014
Tuberculosis Vaccine-Pipeline Insights, 2014
For further information email us at email@example.com
“If a market is growing enormously, you need to understand what’s nourishing it”
DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights.
Pharm Delve reports are known for its extensive detailed information of the Marketed drugs– Global Market, API Market & Manufacturers across the US, Europe and Asia specifically China and India and Phase III Pipeline drugs information. These reports provide whole list of companies interested in your business. It gives you the most up to date information on drug marketed data, patent data, upcoming API with lots of potential in market, interested Generic Drug Companies, Active Pharmaceutical Ingredient (API) Manufacturers to determine which companies and therapies are emerging leaders while understanding the market needs.
Pharm Insights covers the pipeline reports. Mechanism of Action Reports launched has become the most known and on demand amongst the clients. The report has highlighted all the under development drugs falling under the specific MOA with the comparative analysis at various stages and therapeutics assessment by monotherapy and combination products and molecule type drug information. The reports have covered each and every detail of the drugs while chemical information and company profile are considered thoroughly.
Five worth Reason for Spending on these Reports
- Track your closest Competitors
- Identifying potential customers
- Prioritizing new drug intermediates to add to the portfolio
- Uncovering opportunities Globally
- Organic as well as Inorganic Growth
Who can buy these Reports?
- Pharma Companies
- Drug Development Companies
- Generic Manufacturing Companies
- API Manufacturers
Where to buy?
DelveInsight is a Business consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. We provide cutting-edge market and pipeline analysis and API intelligence to the Pharma and Biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.
At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing clear and forthright business recommendations to help clients evaluate potential paths and make vital decisions at all stages of a product’s lifecycle and across multiple business and therapeutic areas.